Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Trabectedin (Primary) ; Dacarbazine
- Indications Leiomyosarcoma; Liposarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Xian-Janssen
- 30 Dec 2016 Planned End Date changed from 1 Feb 2019 to 1 Dec 2018.
- 01 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 19 Jun 2015 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019 as per ClinicalTrials.gov record.